# Biostate AI

> Biostate AI is a Houston biotechnology company selling lower-cost RNA sequencing and analysis tools while assembling clinical datasets for predictive health models. Its wet-lab methods reduce preparation costs; its OmicsWeb and K-Dense tools address the analysis bottleneck created by more data.

- **Founded:** 2023
- **Headquarters:** Houston, United States
- **Founders:** David Zhang (Co-founder and CEO), Ashwin Gopinath (Co-founder and CTO)
- **Products:** Total RNA sequencing, OmicsWeb Copilot, K-Dense, MARE, N-Act
- **Notable:** Published 2026 sequencing price card listing $60 standard and $110 specialty samples., Reported over 10,000 samples processed for more than 150 collaborators and customers by May 2025., Reported access to over 100,000 consented human samples through more than 30 clinical partners in March 2026.

## Products & services

- **Total RNA sequencing** — BIRT and PERD based sequencing service for standard and specialty samples; the 2026 price card lists $60 and $110 per sample respectively, with 10 million reads by default.
- **OmicsWeb Copilot** — Conversational bioinformatics analysis for RNA sequencing data, launched in July 2024.
- **K-Dense** — Automated scientific analysis platform that began as an internal tool, launched in beta in 2025 and later became a Biostate spinout.
- **MARE** — Whole exome DNA sequencing platform described in the company’s January 2026 update.
- **N-Act** — Biomedical multi-omics model under development for disease and treatment prediction.

## Achievements

- Published 2026 sequencing price card listing $60 standard and $110 specialty samples.
- Reported over 10,000 samples processed for more than 150 collaborators and customers by May 2025.
- Reported access to over 100,000 consented human samples through more than 30 clinical partners in March 2026.
- K-Dense spinout selected for the 2026 Accel Atoms cohort backed by Google AI Futures Fund.

## Latest updates

- **2026-03** — K-Dense spinout selected for Accel Atoms AI Cohort 2026 with Google AI Futures Fund backing.
- **2026-03** — Company reported more than 30 clinical partners and access to over 100,000 consented samples.
- **2026-01** — Company reported broader deployment of BIRT and PERD and development of MARE whole exome sequencing.
- **2025-10** — Bayosthiti AI and Narayana Health announced a cardiac AI research collaboration involving 12,000 Indian patients.

## Links

- Website: https://www.biostate.ai/
- LinkedIn: https://www.linkedin.com/company/biostate-ai
- Twitter/X: https://x.com/biostateai
- GitHub: https://github.com/BiostateAI

---

Profile page: https://yespress.io/biostate-ai
Published by YesPress — https://yespress.io
Last updated: 2026-09-29